Clinical trial
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced…
NCT02554812 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT02554812 |
|---|---|
| Title | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) |
| Official title | A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Cancer |
| Intervention type | Drug |
| Interventions | Avelumab, Utomilumab, PF-04518600, PD 0360324, CMP-001 |
| Enrollment | 409 |
| Start date | Nov 9, 2015 |
| Primary completion | Mar 23, 2023 |
| Completion | Mar 23, 2023 |
| First posted | Sep 18, 2015 |
| Last update posted | Jul 30, 2024 |
| Countries | Australia, Canada, France, Japan, Poland, Taiwan, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: